

## CELL BIOLOGY

# Longer metaphase and fewer chromosome segregation errors in modern human than Neanderthal brain development

Felipe Mora-Bermúdez<sup>1,2\*</sup>, Philipp Kanis<sup>2†</sup>, Dominik Macak<sup>2†</sup>, Jula Peters<sup>1†</sup>, Ronald Naumann<sup>1</sup>, Lei Xing<sup>1</sup>, Mihail Sarov<sup>1</sup>, Sylke Winkler<sup>1</sup>, Christina Eugster Oegema<sup>1</sup>, Christiane Haffner<sup>1</sup>, Pauline Wimberger<sup>3</sup>, Stephan Riesenberg<sup>2</sup>, Tomislav Maricic<sup>2</sup>, Wieland B. Huttner<sup>1\*‡</sup>, Svante Pääbo<sup>2,4\*‡</sup>

Since the ancestors of modern humans separated from those of Neanderthals, around 100 amino acid substitutions spread to essentially all modern humans. The biological significance of these changes is largely unknown. Here, we examine all six such amino acid substitutions in three proteins known to have key roles in kinetochore function and chromosome segregation and to be highly expressed in the stem cells of the developing neocortex. When we introduce these modern human-specific substitutions in mice, three substitutions in two of these proteins, KIF18a and KNL1, cause metaphase prolongation and fewer chromosome segregation errors in apical progenitors of the developing neocortex. Conversely, the ancestral substitutions cause shorter metaphase length and more chromosome segregation errors in human brain organoids, similar to what we find in chimpanzee organoids. These results imply that the fidelity of chromosome segregation during neocortex development improved in modern humans after their divergence from Neanderthals.

## INTRODUCTION

The neocortex is unique to mammals and the seat of sensory and motor activities (1). During the evolution of humans, the neocortex increased drastically in size. This is widely considered to be associated with the development of human cognitive abilities (2–8). Quantitative changes that lead to an increase in neocortex size include, for example, increases in the proliferative capacity and numbers of neocortical stem and progenitor cells, and consequently in the numbers of neurons and macroglial cells generated by them (3–8). Comparatively less is known about qualitative changes in neocortex development during hominin evolution that may have occurred concomitant with the increase in neocortex size. However, substitutions and duplications affecting the genes *FOXP2* (9, 10) and *SRGAP2C* (11, 12) have been shown to affect synapse formation and connectivity, resulting in improved learning in mouse models (13, 14).

Brain organoids are useful tissue models for neural progenitors, especially for those in the ventricular zone (15–17). We previously compared the mitotic behavior of neocortical stem and progenitor cells in humans, chimpanzees, and orangutans, using induced pluripotent stem cell (iPSC)-derived cerebral organoids (18). We found that human proliferating apical progenitors (APs), the cells that line the ventricles and from which all other neural cells in the developing neocortex originate, spend around 50% more time in mitotic metaphase than the APs of chimpanzees and orangutans. Metaphase is the step in mitosis where the cell finalizes the preparations to start the segregation and equal distribution of the

chromosomes to the two daughter cells (19). Hence, these differences in metaphase length raise the possibility that the fidelity of chromosome segregation during AP mitosis might differ between humans and apes, with potential consequences for neocortex development and function.

We focus on the roles of three proteins KIF18a [also known as (a.k.a.) Kinesin 8], KNL1 (a.k.a. CASC5), and SPAG5 (a.k.a. astrin), which are highly expressed in the germinal zones of the developing neocortex and are associated with mitotic spindle, kinetochore, and chromosome segregation functions. The kinetochore is a complex, three-dimensional (3D), multiprotein structure mediating the attachment of chromosome centromeres with the ends of kinetochore microtubules (20–22). An important role of kinetochores is to facilitate spindle assembly checkpoint (SAC) function, which regulates the onset of chromosome segregation when chromosomes are correctly aligned at the metaphase plate (23–26). The three proteins stand out because they carry amino acid substitutions found in all present-day humans but are essentially absent in apes and in Neanderthals or Denisovans, i.e., so-called archaic humans, which separated from the evolutionary lineage leading to modern humans about half a million years ago (27). Any functional consequences of these substitutions would thus be unique to modern humans (28–30).

KIF18a, which carries one modern human-specific amino acid substitution, is a motor protein of the kinesin family that is involved in regulating correct chromosome positioning and attachment to kinetochore microtubules, and their bi-orientation within the mitotic spindle (31–33). KNL1, which carries two modern human-specific amino acid substitutions, is part of the outer kinetochore, which is required for attachment of the kinetochores to the microtubules. It is also a main docking site for key proteins of the SAC, such as BubR1 and Mad1, and therefore important for chromosome alignment and segregation (34–37). SPAG5, which carries three modern human-specific amino acid substitutions, is a microtubule-associated protein recruited to kinetochores and

Copyright © 2022  
The Authors, some  
rights reserved;  
exclusive licensee  
American Association  
for the Advancement  
of Science. No claim to  
original U.S. Government  
Works. Distributed  
under a Creative  
Commons Attribution  
License 4.0 (CC BY).

<sup>1</sup>Max Planck Institute of Molecular Cell Biology and Genetics, Dresden, Germany. <sup>2</sup>Max Planck Institute for Evolutionary Anthropology, Leipzig, Germany. <sup>3</sup>Department of Gynecology and Obstetrics, Technische Universität Dresden, Dresden, Germany. <sup>4</sup>Okinawa Institute of Science and Technology, Onna-son 904-0495, Japan.

\*Corresponding author. Email: mora@mpi-cbg.de (F.M.-B.); huttner@mpi-cbg.de (W.H.); paabo@eva.mpg.de (S.P.)

†These authors contributed equally to this work; listed in alphabetical order.

‡These authors jointly supervised the work; listed in alphabetical order.

is important for the stability of attachment of kinetochores to microtubules (38–41).

We show here that APs in the embryonic neocortex of mice where the modern human substitutions in KIF18a and KNL1 have been introduced by genome editing exhibit longer metaphases, more SAC-positive kinetochores, and fewer mis-segregating chromosomes. In converse experiments, where human embryonic stem cells (ESCs) that carry the ancestral variants of KIF18a and KNL1 are used to generate cerebral organoids, shorter metaphases, less SAC-positive kinetochores, and more chromosome segregation defects are observed in APs. Together, our data suggest that the three amino acid substitutions in KIF18a and KNL1 cause fewer chromosome inheritance errors to occur in APs of modern humans than in archaic humans and apes.

## RESULTS

### More SAC-positive kinetochores in human than chimpanzee APs


An active SAC, triggered, e.g., by one or more kinetochores not being properly attached to kinetochore microtubules, delays anaphase onset and therefore prolongs metaphase (23, 42). We first asked whether iPSC-derived cerebral organoids (below referred to as “organoids”) can serve as models to study SAC activity during neocortex development. As determined by immunofluorescence, the number of BubR1-positive kinetochores, a marker for active SACs, did not differ between APs that had formed a metaphase plate in human neocortex samples of gestation week (GW) 11 to GW12, and those of human organoid APs of days 30 to 32 (13.6 versus 12.5,

$P > 0.05$ ; Fig. 1, A, B, and D). In agreement with this, another active SAC marker, Mad1, was also found to be present at kinetochores in similar numbers in the fetal and organoid APs (12.8 versus 12.3,  $P > 0.05$ ; fig. S1, A, B, and D). Organoids can therefore be used to study the number of SAC-positive kinetochores in cerebral tissue APs.


To investigate whether the previously described metaphase prolongation in human relative to chimpanzee APs (18) may be related to SAC activity, APs in human and chimpanzee iPSC-derived organoids were studied. The numbers of BubR1-positive kinetochores in fetal human neocortex and human organoid APs were 46 and 34% higher, respectively, than in chimpanzee organoid APs ( $P < 0.001$  and  $P < 0.01$ , respectively; Fig. 1, A to D). Also, the numbers of Mad1-positive kinetochores were similarly 51 and 45% higher (both  $P < 0.0001$ ) in the fetal human neocortex and human organoid APs, respectively, than in chimpanzee organoid APs (fig. S1, A to D). Thus, human metaphase APs have more SAC-positive kinetochores than chimpanzee APs.

### Fewer lagging chromosomes in human than chimpanzee APs

Differences in metaphase length and SAC signaling could affect chromosome segregation accuracy. To test this possibility, the APs with chromosomes, or large chromosome fragments, lagging in anaphase and telophase in human and chimpanzee iPSC-derived organoids were quantified by serial confocal microscopy (Fig. 2, A to D). As expected for a process where mistakes need to be minimized to ensure normal physiological development, lagging chromosomes were rare (Fig. 2E). Nevertheless, the percentage of mitotic APs with lagging chromosomes was higher in chimpanzee than in human organoids (8 of



**Fig. 1. More SAC-positive kinetochores in modern human than chimpanzee APs.** (A to C) APs in metaphase stained with DAPI (4',6-diamidino-2-phenylindole) and immunostained for the SAC marker BubR1 (red in merges) and the kinetochore marker CREST (green in merges). Arrowheads indicate overlap of BubR1 and CREST immunoreactivity within the metaphase plate. (A) GW12 human neocortex; (B) day 30 human iPSC-derived cerebral organoid; and (C) day 30 chimpanzee iPSC-derived cerebral organoid. White dashed lines, ventricular surface. Scale bar, 5  $\mu$ m. (D) Quantification of kinetochores positive for BubR1 per AP metaphase plate, for the tissues in (A) to (C) (GW11 to GW12, days 30 to 32). Data are the means  $\pm$  SEM of  $\geq 41$  APs from  $\geq 3$  independent experiments each, with 3 neocortex samples and  $\geq 5$  organoids each. Brackets with \*\* $P < 0.01$ ; \*\*\* $P < 0.001$ ; n. s., nonsignificant (Kruskal-Wallis test with Dunn's multiple comparisons correction).



**Fig. 2. Fewer lagging chromosomes in modern human than chimpanzee APs.** (A to D) Mitotic APs in days 30 to 32 modern human iPSC-derived cerebral organoids stained with DAPI. Examples of APs in anaphase (A) and telophase (B) without lagging chromosomes, and in anaphase (C) and telophase (D) with lagging chromosomes, or large chromosome fragments (arrowheads). White dashed lines, ventricular surface. Scale bar, 5  $\mu$ m. (E) Cumulative quantification (see Materials and Methods) of the percentages of AP divisions with lagging chromosomes in days 30 to 32 modern human (grayscale) and chimpanzee (Chimp, green) iPSC-derived cerebral organoids. Data are the sum from  $\geq 5$  independent experiments and a total of  $\geq 342$  AP divisions (only anaphase or telophase) each. Each bar shows the data for the sum of mitotic APs in anaphase plus telophase, with the stacked percentages for telophase (dark shade) and anaphase (light shade) being indicated separately.

342 versus 5 of 385, or 2.3% versus 1.3%; Fig. 2E). Also, the majority of lagging chromosomes in both species were found in telophase rather than in anaphase (10 of 13 cells; Fig. 2E), suggesting that those lagging chromosomes are unlikely to be rescued by the end of cell division. Thus, AP chromosome segregation fidelity is higher in modern humans than in chimpanzees.

### Mice “humanized” for *KIF18a*, *KNL1*, and *SPAG5* reveal genes involved in metaphase prolongation

To ask whether molecular changes unique to modern humans, compared to not only apes but also Neanderthals and Denisovans, might lead to differences in AP mitosis, we investigated whether the six modern human-specific amino acid substitutions in *KIF18a*, *KNL1*, and *SPAG5* may influence mitotic phase duration in APs. In mice, where the amino acids at those six positions are naturally identical to archaic humans and apes, we used CRISPR-Cas9 technology to change them to the modern human variants [“modern-humanized” mice, or for simplicity, referred to as humanized (h) mice; Fig. 3, A and B; see also Materials and Methods and fig. S2 for generation and verification of the lines].

First, a mouse line humanized for all six amino acids was examined, i.e., one in *KIF18a* (R67K), two in *KNL1* (H159R and G1086S), and three in *SPAG5* (P43S, E162G, and D410H; Fig. 3A), referred to as h*KIF18a*-h*KNL1*-h*SPAG5* mice (Fig. 3B). Live-tissue imaging of AP divisions in organotypic slice cultures of embryonic day (E) 11.5 h*KIF18a*-h*KNL1*-h*SPAG5* neocortex showed an increase from 4.6 to 5.6 min in mean metaphase length relative to wild-type (wt) mice (i.e., plus 22%,  $P < 0.001$ ; Fig. 3, C, D, and J). To find out whether substitutions in all three proteins participated in the metaphase prolongation, h*KIF18a*-h*KNL1* mice humanized for the three amino acid substitutions in *KNL1* and *KIF18a* were examined. These mice showed an increase in AP metaphase duration from 4.6 to 5.8 min


( $P < 0.001$ ) that did not differ ( $P > 0.05$ ) from the h*KIF18a*-h*KNL1*-h*SPAG5* mice with the six amino acid substitutions (Fig. 3, C, E, and J). This suggests that substitutions in both, or either of, h*KNL1* and h*KIF18a*, but not h*SPAG5*, are involved in AP metaphase prolongation.

Next, three mouse lines were examined, each carrying one of the three genes in a humanized form. APs in the h*KNL1* and h*KIF18a* lines showed a tendency toward longer metaphases compared to the wt (by 11 and 13%, respectively, or 5.1 and 5.2 min instead of 4.6 min), albeit not significantly so ( $P > 0.05$ ; Fig. 3, F, G, and J). This suggests that substitutions in h*KNL1* and h*KIF18a* contribute additively to the AP metaphase prolongation.

To further dissect the role of individual amino acid substitutions, two mouse lines were examined where each carries only one of the two substitutions in *KNL1*. No significant differences in metaphase length were found, neither between the two lines and wt mice nor between the two lines themselves [4.2 min (h*KNL1* substitution 1) versus 4.6 min (h*KNL1* substitution 2) versus 4.6 min (wt), respectively; fig. S4, see also Fig. 3]. This suggests that both substitutions are required for the *KNL1* contribution to metaphase prolongation.

In contrast, in h*SPAG5* mice, the length of the AP metaphase was 4.4 min and hence similar to wt mice (Fig. 3, H and J), indicating that the three substitutions in h*SPAG5* are not involved in the metaphase prolongation in the h*KIF18a*-h*KNL1*-h*SPAG5* mice. It also shows that modern humanization of any three amino acids in a protein involved in mitosis and kinetochore function is not in itself sufficient to prolong AP metaphase.

Notably, the durations of prometaphase, which precedes metaphase, and of anaphase, which follows metaphase, did not show any significant changes in any of the mouse lines analyzed (Fig. 3, I and K, and fig. S4, A and C). Together, these results suggest a specific role of the amino acid substitutions in *KNL1* and *KIF18a* in the prolongation of AP metaphase seen in modern humans.



**Fig. 3. Mice humanized for *KIF18a*, *KNL1*, and *SPAG5* reveal genes involved in metaphase prolongation.** (A) Schematic representation of the domain structure of *KNL1*, *KIF18a*, and *SPAG5*, carrying a total of six amino acid (aa) residue differences between modern humans (h) and archaic humans (a): *KNL1*, H<sub>a</sub>159R<sub>h</sub>, and G<sub>a</sub>1086S<sub>h</sub>; *KIF18a*, R<sub>a</sub>67K<sub>h</sub>; *SPAG5*, P<sub>a</sub>43S<sub>h</sub>, E<sub>a</sub>162G<sub>h</sub>, and D<sub>a</sub>410H<sub>h</sub>. Note that in wt mice, these six amino acid residues are identical to those in archaic humans and apes. (B) C57Bl6/NCrl wt mice were gene edited using CRISPR-Cas9 (see Materials and Methods) to change the wt (Neanderthal-like) amino acid residue(s) specified in (A) to the modern human variants. Five different humanized (h) mouse lines were generated as indicated. (C to H) Live-tissue imaging of the indicated mitotic phases of APs in organotypic coronal slice cultures of neocortex of E11.5 mice of the indicated genotypes (see Materials and Methods). Zero (0) minute is metaphase plate onset. Time-lapse intervals are 1.5 min. Red lines indicate the duration of metaphase, white dashed lines the ventricular surface. Scale bar, 5 μm. (I) Times between the start of chromosome congression and metaphase plate onset (referred to as "Congression" or "Prometaphase"); (J) between metaphase plate onset and chromatid segregation onset (referred to as "Metaphase plate" or "Metaphase"); and (K) between the onset of chromatid segregation and onset of chromosome decondensation (referred to as "Anaphase"), for APs in the six neocortical tissues described in (C) to (H). Data are the means ± SEM of ≥50 APs from ≥3 independent experiments, with a total of ≥5 neocortices, for each of the six lines. Brackets with \**P* < 0.05; \*\*\**P* < 0.001 (Kruskal-Wallis test with Dunn's multiple comparisons correction).




We also explored whether the modern human-specific changes in *KIF18a* and *KNL1* may influence general aspects of cortical development. However, we did not observe any effects on the overall morphology, thickness, or perimeter of the neocortex in adult mice humanized for *KIF18a* and *KNL1* (fig. S3, A to C). Consistent with this, the adult mice did not show any change in the distribution or numbers of Ctip2<sup>+</sup> deep-layer neurons and Brn2<sup>+</sup> upper-layer neurons (fig. S3, D to F).

### APs in human organoids “ancestralized” for *KIF18a* and *KNL1* have a shorter metaphase

To investigate whether the amino acid substitutions in *KIF18a* and *KNL1* prolong metaphase in a modern human genetic background, we used CRISPR technology to change the relevant single codon in *KIF18a* and the two codons in *KNL1* back to the ancestral, Neanderthal-like state in the H9 ESC line. Individual cells subjected to the relevant RNA guides and donor DNAs were expanded to cell lines, among which we selected two independent ancestralized lines [aKif18a-aKNL1 lines 1 (L1) and 2 (L2)] and two lines where none of the three codons had been changed [“control” lines 1 (L1) and 2 (L2); Fig. 4A] on the basis of sequencing across the edited sites. To exclude mono-allelic deletions (43) and loss of heterozygosity at the

CRISPR target sites as well as big chromosomal deletions or duplications elsewhere in the genome, the four lines were characterized by quantitative polymerase chain reaction (PCR) of the target sites, by genotyping of heterozygous single nucleotide polymorphisms up- and down-stream of the sites, as well as by low coverage whole-genome sequencing. Furthermore, mRNA expression of *KIF18a* and *KNL1* was found to be similar among all four lines and similar to the expression in the cell line from which the cells were derived from (table S2).

Organoids were generated from the four lines, and live-tissue imaging of AP divisions in organotypic slice cultures was performed after 27 to 30 days of culture. The average metaphase length of APs in the organoids grown from the two ancestralized lines was 7.0 min, whereas it was 9.2 min for the control lines, i.e., a 24% decrease upon ancestralization ( $P < 0.0001$ ). These results did not depend on any single control or aKIF18a-aKNL1 line, as AP metaphases were shorter in each of the aKIF18a-aKNL1 lines than in the control lines and the original nonedited ESC line (fig. S5). Similar to the situation in the humanized mice, the durations of AP prometaphase and anaphase were not affected in any of the organoids (Fig. 4, B to D, and fig. S5, E and F). In conclusion, the mice and the human organoids that are humanized and ancestralized, respectively, for *KIF18a* and



**Fig. 4. APs in human organoids ancestralized for *KIF18a* and *KNL1* have a shorter metaphase than modern human controls.** (A) Human H9 ESCs were gene edited using CRISPR technology to convert the indicated three amino acids in *KIF18a* and *KNL1* from the modern human (h) to the ancestral (a) Neanderthal-like states, and used to grow cerebral organoids (see Materials and Methods). (B and C) Live-tissue imaging of the indicated mitotic phases of APs in organotypic slice cultures of days 27 to 30 cerebral organoids grown from the indicated control (B) and ancestralized (C) line. Zero (0) minute is metaphase plate onset. Time-lapse intervals are 2.08 min. Red lines indicate the duration of metaphase, white dashed lines the ventricular surface. Scale bar, 5  $\mu$ m. (D) Times between the start of chromosome congression and metaphase plate onset (referred to as “Congression”), between metaphase plate onset and chromatid segregation onset (referred to as “Metaphase plate”), and between chromatid segregation onset and general chromosome decondensation onset (referred to as “Anaphase”), for APs in the two types of organoids as described for line 1 in (B) and (C). Data are the means  $\pm$  SEM for organoids grown from the two control and the two ancestralized lines (L1, L2) and comprise  $\geq 119$  APs from four independent experiments, with  $\geq 7$  organoids, for each of the lines. Bracket with \*\*\*\* $P < 0.0001$  (Mann-Whitney  $U$  test).

KNL1 show that the three modern human-specific amino acid substitutions in these two proteins specifically prolong metaphase in APs.


### Metaphase prolongation arises during cerebral cortex development

Our previous work (18) demonstrated that the increased metaphase duration in human APs relative to chimpanzee and orangutan APs occur in organoids grown for approximately 30 days (as in the present study) but not in non-neural cells, including the iPSCs used to generate the organoids, or in organoids at 52 days. It thus seems specific to early stages of cerebral cortical development in humans. To test whether this holds true for the metaphase prolongation caused by the modern human-specific substitutions, the durations of mitotic phases were measured in monolayer cultures of the H9 ESCs used to generate the organoids. No differences in the duration of metaphase (fig. S6, A to E) or other mitotic phases (fig. S6, A to D, F, and G) were observed between aKIF18a-aKNL1 and control H9 ESCs. Thus,

the prolongation of AP metaphase in ancestralized KIF18a-KNL1 human organoids arises during the early development of the organoid tissue, similar to what is observed in human and chimpanzee organoids.

### More SAC-positive kinetochores in humanized than wt mouse APs

To test whether the prolongation of AP metaphase in the mice humanized for KIF18a and KNL1 is associated with a change in the number of SAC-positive kinetochores, E11.5 mouse neocortices were immunostained for BubR1. In metaphase APs of mice humanized for KIF18a and KNL1, the average number of BubR1-positive kinetochores was 7.1, whereas it was 5.5 in wt mice, i.e., a 29% increase upon humanization ( $P < 0.01$ ; Fig. 5, A to C). In agreement with this, the number of Mad1-positive kinetochores in the humanized mouse APs was 7.5, whereas it was 5.5 in wt mice, i.e., a 36% increase ( $P < 0.01$ ; fig. S7, A to C).



**Fig. 5. More SAC-positive kinetochores in humanized mouse APs and fewer SAC-positive kinetochores in ancestralized human organoid APs.** (A, B, D, and E) APs in metaphase stained with DAPI and immunostained for BubR1 (red in merges) and the kinetochore marker CREST (green in merges). Arrowheads indicate overlap of BubR1 and CREST immunoreactivity within the metaphase plate. (A) Neocortex of E11.5 wt (ancestral-like) mouse; (B) neocortex of E11.5 mouse humanized for *Kif18a* and *Kn11*; (D) modern human nonedited day 27 cerebral organoid (control line 1); (E) day 29 organoid ancestralized for *KIF18a* and *KNL1* (edited line 1). White dashed lines, ventricular surface. Scale bar, 5  $\mu$ m. (C) Number of BubR1-positive kinetochores per AP metaphase plate in mouse neocortex as described in (A) and (B). Data are the means  $\pm$  SEM of  $\geq 41$  APs from three independent experiments, with a total of  $\geq 5$  neocortices, for each of the two types of mice. Bracket with \*\* $P < 0.01$  (Mann-Whitney *U* test). (F) Number of BubR1-positive kinetochores per AP metaphase plate for days 27 to 30 organoids (e.g., D and E). Data are the means  $\pm$  SEM of  $\geq 54$  APs from six independent experiments, with a total of  $\geq 10$  organoids, for each of the two ESC lines. Bracket with \*\*\* $P < 0.001$  (Mann-Whitney *U* test).

### Fewer SAC-positive kinetochores in ancestralized than modern human organoid APs

Similarly, APs in human ESC-derived organoids ancestralized for KIF18a and KNL1 were examined. They had an average of 8.9 BubR1-positive kinetochores, whereas the control organoids had an average of 12.8 BubR1-positive kinetochores, i.e., a 30% decrease upon ancestralization ( $P < 0.001$ ; Fig. 5, D to F). Corresponding numbers for MAD1-positive kinetochores were 7.5 and 10.4, respectively, i.e., a 28% decrease ( $P < 0.0001$ ; fig. S7, D to F). Notably, the APs analyzed were all positive for FoxG1, indicating cortical or telencephalic identity (fig. S7G). Thus, the number of SAC-positive kinetochores in APs increases in mice humanized for KIF18a and KNL1, while it decreases in human organoids ancestralized for these proteins.

### Fewer lagging chromosomes in humanized than in wt mouse APs

To test whether the persisting SAC activity and the delayed anaphase onset might lower the incidence of chromosomal segregation errors, APs showing lagging chromosomes were quantified in anaphase or telophase in the neocortex of E11.5 mice humanized for KIF18a and KNL1 (Fig. 6, A to D). As for modern human and chimpanzee organoids (Fig. 2E), few mitotic APs had lagging chromosomes (Fig. 6I). However, the proportion of lagging chromosomes in wt mice was essentially twice that of the mice humanized for KIF18a and KNL1 (7 of 323 versus 4 of 358, or 2.2% versus 1.1%; Fig. 6I). Similar to the situation in the modern human and chimpanzee organoids (Fig. 2E), the majority of the mitotic APs with lagging chromosomes (8 of 11) were seen in telophase rather than in anaphase, suggesting that most of these segregation defects do not become rescued by the end of cell division.

Given the relatively small numbers of observations of lagging chromosomes, these were also quantified in the mice humanized for all six residues in KIF18a, KNL1, and SPAG5. The proportion of lagging chromosomes in these mice was 4 of 314, similar to that observed in the mice humanized for KIF18a and KNL1 only (see above and Fig. 6I).


### More lagging chromosomes in ancestralized than in modern human organoid APs

Similarly, the fidelity of chromosomal segregation was also analyzed in the organoids ancestralized for KIF18a and KNL1. The proportion of mitotic APs with lagging chromosomes in the organoids ancestralized for KIF18a and KNL1 was more than twice that of the control organoids (9 of 389 versus 4 of 410, or 2.3% versus 1.0%; Fig. 6, E to I). Again, 10 of 13 cells with lagging chromosomes were in telophase rather than in anaphase.

In conclusion, the analyses of the neocortex of the mice humanized for KIF18a and KNL1 and of the human cerebral organoids ancestralized for KIF18a and KNL1 show that the three modern human-specific amino acid substitutions in KIF18a and KNL1 prolong the mitotic metaphase of APs and decrease the occurrence of mitotic APs with chromosome segregation defects.

## DISCUSSION

In the present study, we focus on modern human-specific amino acid substitutions in mitotic spindle and kinetochore proteins and their effects on the divisions of APs during neocortical development.



**Fig. 6. Fewer lagging chromosomes in humanized mouse APs, and more lagging chromosomes in ancestralized human organoid APs.** (A to H) Mitotic APs stained with DAPI in the neocortex of E11.5 wt mice and mice carrying humanized *hKif18a-hKnl1* (A to D) and in days 27 to 30 control cerebral organoids (line 2) and organoids with ancestralized *aKif18a-aKnl1* (line 2, E to H). Examples of APs in anaphase (A and E) and telophase (B and F) without lagging chromosomes, and in anaphase (C and G) and telophase (D and H) with lagging chromosomes, or large chromosome fragments (arrowheads). White dashed lines, ventricular surface. Scale bar, 5  $\mu$ m. (I) Cumulative quantification (see Materials and Methods) of the percentages of AP divisions with lagging chromosomes for the tissues described in (A) to (H), as well as for the neocortex of E11.5 mice carrying humanized *hKif18a-hKnl1-hSpag5*. The mouse data are the sum of  $\geq 314$  AP divisions in anaphase or telophase from six experiments for each of the three types of mouse neocortex, and the human organoid data are the sum of  $\geq 389$  AP divisions from six experiments for each of the two types of organoids (sums of lines 1 and 2). The percentages for telophase (dark shade) and anaphase (light shade) are indicated separately.

There are several reasons for this. First, previous work has shown that metaphase is longer in the APs of modern humans than in those of apes (18). Second, this difference appears to be unique to the early stages of cerebral cortical tissue development, as it is not seen in non-neural cells or in organoids at late stages (18). Third, among around 100 genes carrying essentially fixed amino acid substitutions characteristic of modern humans compared to archaic humans (28), the three genes studied here—*KNL1*, *KIF18a*, and *SPAG5*—are highly expressed in the developing neocortex, predominantly in the ventricular zone, the primary germinal layer where APs reside (44). Fourth, the three proteins encoded by these genes carry a total of six amino acid substitutions unique to modern humans (45). This is more than expected given the small total number of such amino acid differences. Fifth, these three proteins are involved in kinetochore function, a key process during metaphase (25).

When we introduce these six modern human-specific amino acid substitutions into mice, this results in a prolongation of metaphase in APs (Fig. 3J), reminiscent of what is seen when modern humans are compared to apes. The three substitutions in the two proteins *KNL1* and *KIF18a* are enough to elicit the full effect, whereas the substitutions in either of the two proteins only show a tendency for a metaphase prolongation of intermediate magnitude. In contrast, the three substitutions in *SPAG5* have no effect. These data are consistent with the fact that the substitutions in *KIF18a* (31) and *KNL1* (46, 47) are located in, or close to, functionally relevant domains or motifs, whereas this is not the case for *SPAG5* (see Fig. 3A) (38).

When the three modern human-specific amino acids in *KNL1* and *KIF18a* are changed to the ancestral states shared by apes and archaic humans in human ESCs, this results in a shortening of the metaphase in APs in organoids, whereas other phases of AP mitosis are not affected (Fig. 4D). Thus, the “modern humanization” of *KNL1* and *KIF18a* in mice and the “ancestralization” of these genes in human organoids yield congruent results, suggesting that the amino acid substitutions specific to modern humans cause a prolongation of the metaphase in APs. It is noteworthy that the magnitude of the shortening of AP metaphases seen in the ancestralized organoids is close to that previously observed between modern human and chimpanzee organoids (18). It is therefore possible that the three amino acid substitutions in *KIF18a* and *KNL1* are largely responsible for the difference in AP metaphase length between present-day humans and apes. Given that the three ancestral amino acids are shared between chimpanzees and archaic humans, this implies that most, if not all, of the lengthening of AP metaphase evolved in modern humans subsequent to the divergence from archaic humans around half a million years ago.

A concern when performing genome editing is unintended effects that may affect the target sites, notably deletions (43, 48) that may not be detected when the target site is sequenced (49). To exclude this, we determined the copy number of the locus after editing and verified that polymorphic positions up- and downstream of each site remained heterozygous after editing. In preliminary experiments, we identified two cellular clones that carried the ancestralized sites, but in one case in addition a deletion of one allele of *KNL1* and in the other case a deletion of one allele of *KIF18a*. Both these clones show a shortening of AP metaphase of similar magnitude as the diploid clones (fig. S8A). This suggests that mitotic APs harbor sufficient *KIF18a* and *KNL1* protein so that one allele of either of the genes can be inactivated without detectable consequences for the aspects of cell division measured here. Corresponding decreases in

SAC-positive kinetochores and increases in lagging chromosomes are also seen (fig. S8, B to D).

Two other amino acid substitutions that have become essentially fixed in modern humans after the split from the ancestors of Neanderthals and Denisovans have recently been analyzed. The first case is an amino acid substitution in the splice protein NOVA1 that is proposed to affect brain organoid morphology when edited to the ancestral state (50). However, this effect may be influenced by unintended hemizygous deletions (49) [but see also (51)]. The second is an amino acid substitution in the enzyme adenylosuccinate lyase, which decreases the stability of the protein and reduces purine biosynthesis when edited to the modern human-like state in mice and increases purine biosynthesis when ancestralized in human cells (52). It is unknown what further organismal effect this has, but when humans and great apes are compared, the reduction in purine synthesis is particularly pronounced in the brain (52).

It is notable that the modern human-specific amino acid substitutions in *KNL1* and *KIF18a* result in more kinetochores being associated with components of the SAC (Fig. 5 and fig. S7) and in fewer lagging chromosomes or chromosomal fragments in mitotic APs (Fig. 6). Therefore, these substitutions are likely to result in higher accuracy of chromosome segregation in APs during neocortex development. This may have significant consequences. During the early stage of this development, APs undergo symmetric proliferative divisions that increase the AP pool size (3–7, 53). Any chromosome segregation error that occurs in an AP at this stage will therefore be amplified by the natural AP proliferation, resulting in more APs with aberrant chromosome numbers. When APs switch to asymmetric divisions at the onset of cortical neurogenesis (3–7, 53), chromosomal aberrations may be transmitted to their progeny, i.e., the basal progenitors, cortical neurons, and macroglial cells. Therefore, any radial unit derived from an AP with a chromosome segregation error, and hence the cortical column that contains this unit (1, 54), might be functionally affected. Very different rates of neuronal aneuploidy in the brain have been reported in the literature. However, we note that the lagging chromosome percentages seen here are consistent with the percentages of aneuploidy reported for the human brain in recent studies (55–57). Mis-segregation may also result in apoptosis and loss of progenitors and the radial units they would have generated. In either case, consequences for the functionality of the entire neocortex area harboring an affected radial unit may ensue, for example, for excitatory pyramidal neurons and their numerous connections and projections. In addition, lingering chromosome segregation defects may have a variety of pleiotropic effects because of perturbed nuclear organization, increased occurrence of micronuclei, and imbalances in gene expression (58, 59). These effects may tend to be more profound than the effects of somatic point mutations that may be involved, for example, in autism spectrum disorder (60). The present data imply that the probability of any such detrimental effects of chromosomal mis-segregation may be lower in modern humans than in Neanderthals, Denisovans, and apes. Further work is needed to address the importance of these effects for traits characteristic of modern humans.

## MATERIALS AND METHODS

### Mice

All mouse experiments were performed according to the German Animal Welfare Legislation (“Tierschutzgesetz”) after approval by



the Federal State Authority Landesdirektion Sachsen. All procedures were overseen by the Institutional Animal Welfare Officer of MPI-CBG. Mice used for this study were kept in standardized and pathogen-free conditions at the Biomedical Services Facility (BMS) of MPI-CBG, with unlimited access to food and water, and in a 12-hour/12-hour light/dark cycle. Because the sex of the embryos was unlikely to influence the results in this study, it was not taken into consideration. Embryonic day (E) 11.5 embryos were used throughout. E0.5 was defined as noon of the day of vaginal plug identification.

### Human tissue

Fetal human neocortex tissue (PCW 11-12) was obtained from the Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Carl Gustav Carus of the Technische Universität Dresden, with informed written maternal consent and with approval of the Clinic's Ethical Review Committees. PCW 11-12 corresponds to an early neurogenesis stage. The age of fetuses was assessed by ultrasound measurements of crown-rump length and other standard criteria of developmental stage determination. Because of protection of data privacy, the sex of the human fetuses from which neocortical tissue was obtained cannot be reported. The sex is unlikely to influence the results in the present study.

### Mouse genome engineering

For introduction of point mutations mimicking the modern human-specific changes, genome edited mouse lines were established using CRISPR-mediated homology directed repair (HDR) in isolated mouse zygotes, using the pronuclear injection delivery method.

The following guide RNAs (gRNAs) with protospacers targeting the genomic positions of the desired changes in *Kif18a*, *SPAG5*, and *KNL1* were either purchased as AltR crRNAs (IDT) or produced by in vitro transcription from a PCR template containing the T7 promoter followed by the gRNA sequence and the optimized gRNA scaffold (61) using the esiSCRIBE In Vitro Transcription Kit (Eupheria Biotech) following the manufacturer's instructions:

*Kif18a\_R67K\_sg1*; CAAATTTTGATATTAATAAA  
*Kn1\_H109R\_sg1.1*; CATTTGCATGTTTCCTTTCA  
*Kn1\_G910S\_sg2.1*; TTTCTGAATGAACTTCTGTC  
*Spag5\_P43S\_sg1.2*; GCACAGGTATGGGGTCAGCG  
*Spag5\_E164G\_sg2.2*; AAGCTCTCTAAATGAATCTT  
*Spag5\_D380H\_sg3/cr3*; AGGACAGTACTTCAGAGACA

As HDR templates, the following oligonucleotides were used:  
*Kif18a\_R67K*;

5'-GCTTGGTTGTGTGTTCAAAAACCTCCATTTGAGTT-  
 G A A G T T T C A T C A A A G A C A G C A T C A A A T A -  
 CAAACTTCAGATCTTTATTTTGTTTTGTAGTAATAT-  
 CAAAATTTGTAGTTTTCTTTCTGTGAAA-3'

*Kn1\_H109R*;

5'-TGCTGTCAGATCCATCTGGTTTTTCATCTGAAAAGAT-  
 GACTGTCTGATCATTTGCATGTTTGCCTCGCGTTG-  
 C A G T C T G T A A T T G A G A A C T A T A A T -  
 GAAAAATAGAAATATTAGATCAAATATAAT-3'

*Kn1\_G910S*;

5'-ATTCTCTGGAAATGTAATACTCTTGTTTTGTAG-  
 GCTAAGGCTTTTCTTCTCTGAGTTTTGGATGA-  
 CAGAAGTTCATTCAGAAATCCAGGCTTTTGTGCATCATT-  
 AGTTTCTCTCCAAGCCC-3'

*Spag5\_P43S*;

5'-AGTACTCCTCTCCGAGAGCTTAAACTACAGC-  
 CCGAGGCCCTCGCCGATTCAGGGAAAGGTAGTAGCAT-  
 GATTAGTGCACACTGACCCCATACCTGTGCAGGCTGGAGCT-  
 GAAGGTGAGATTTTTAGCTTCACTGGGCT-3'

*Spag5\_E164G*;

5'-TGTTAGGCTGTCTTCCACACAAGGTGC-  
 CACCTCCTTCCCACAGATCTTCTAGCCCCAAGCTGC-  
 CATTAGAGAGCTTTTGTCTCTCTGCTGTGGTATCTA-  
 AGTGAGCCTGGAGCATCAGGTC-3'

*Spag5\_D380H*;

5'-CAGGATGCTGCCGTTGGCAACACACCCCTCGCCAC-  
 GTGTTCTGTGGGCACTTCTTTACTCCTCCAGCACCCT-  
 GGAGGTAGGCACAAAACACAGTACTTCAGAGACAGAGC-  
 GCCTCCTCTGGGGT-3'

### Donor/background/CRISPR-Cas9 injection

C57Bl6/NCrl mice were mated after superovulation [46 hours between pregnant mare serum gonadotrophin (PMSG) and human chorionic gonadotrophin (HCG)] at the midpoint of the dark period (12 hours/12 hours, 4:00 a.m. to 4:00 p.m. light circle). After positive plug detection in the morning, the cumulus complexes were isolated and zygotes were removed with a treatment of hyaluronidase [final concentration of 0.1% (801 U/ml)]. CRISPR-Cas9 solutions were injected into the male pronucleus of fertilized zygotes by using a motor-driven manipulator-based microinjection stage. About 2 hours after injections, the surviving embryos were transferred into Crl:CD1(ICR) pseudopregnant recipient female mice (ca. 20 embryos per recipient).

### Embryo transfer

The recipient mice were mated with vasectomized males Crl:CD1 (ICR). After detection of a copulation plug in the morning of the transfer day, pseudopregnant mice were used for unilateral surgical embryo transfer into the oviduct as described (62). Anesthesia was induced by intraperitoneal injection of ketamine/xylazine and acepromazine (63).

### Mouse lines for single genes and gene combinations

*hKNL1-hKIF18a* and *hSPAG5* mice, each carrying three missense changes, were generated by first combining gRNAs for all three changes and then repeating cycles for those changes not obtained in the previous rounds. The *hKNL1* and *hKIF18a* lines were generated independently from the combined *hKNL1-hKIF18a* line, as *Kn1* and *Kif18a* reside on the same mouse chromosome. The *hKNL1-hKIF18a-hSPAG5* line was generated by crossing the *hKNL1-hKIF18a* and *hSPAG5* lines.

Candidate mice for each line were genotyped with primers and conditions described in table S1. Positive mice for each line were back-crossed with wt C57Bl6/NCrl mice and genotyped for at least six generations before experiments.

### Genotyping of mice

Genomic DNA from tail biopsies and buccal swabs of 3-week-old pups were prepared using the Sigma Extract-N-Amp Tissue Kit following the manufacturer's instruction but using only half of the described volumes. The target regions were amplified by PCR in a total volume of 25 µl using the Phusion Flash Mastermix (Thermo Fisher Scientific) with 2 µl of genomic tail DNA, 0.25% dimethyl sulfoxide, and 0.5 µM forward and reverse primer. Primer sequences (target-seq-primer) and PCR conditions are in table S1. Products were Sanger sequenced either with the forward and reverse PCR primers or if required with internal sequencing primers. Primary candidates have been identified by sequence alignments of potentially modified PCR fragments against the wt and modified reference

sequence. The products from putatively edited mice were cloned (TOPO) and verified by Sanger sequencing of 10 to 20 randomly selected clones. Founders carrying the respective genome modification either homo- or heterozygously were propagated and genotyped by Sanger sequencing of PCR fragments. From the second generation onward, allele-specific PCRs were performed on 2  $\mu$ l of crude buccal DNA in a total of 10  $\mu$ l using the REExtract-N-Amp PCR ready Mix (Sigma-Aldrich) according to the manufacturer's protocol using 0.5  $\mu$ M forward, reverse, and mutant primer. The readout is done on standard agarose gels. Primers and PCR conditions are in table S1.

### Expression analysis of edited genes in humanized mice

For Sanger sequencing and real-time qPCR, total RNA was isolated from E11.5 wt and humanized mouse dorsolateral telencephalon using the RNAeasy Micro Plus Kit (Qiagen) according to the manufacturer's instructions. cDNA was synthesized using the Maxima First-Strand cDNA Synthesis Kit (Thermo Fisher Scientific). The expression of *Kif18a*, *Kn11*, and *Spag5* in the wt and humanized embryonic mouse telencephalon was confirmed by PCR, using generated cDNA as templates, followed by Sanger sequencing of the PCR products. Wt and gene-edited sequences were mapped to the *Kif18a*, *Kn11*, and *Spag5* genes, respectively, using Geneious Prime (version 2020.2.4). Data showed the expression of only the wt *Kif18a*, *Kn11*, and *Spag5* in E11.5 wt embryonic mouse telencephalon, and the expression of only the gene-edited *hKif18a*, *hKn11*, and *hSpag5* in E11.5 humanized hKIF18a-hKNL1-hSPAG5 (see Fig. 3A) embryonic mouse telencephalon (fig. S2, A to F). Relative mRNA levels of *Kif18a*, *Kn11*, and *Spag5* to *Actb* in wt and humanized embryonic mouse telencephalon were quantified by qPCR, which was performed using the FastStart essential DNA green master (Roche) and LightCycler 96 Instrument (Roche). Gene expression analyses by qPCR showed that the relative mRNA levels of *Kif18a*, *Kn11*, and *Spag5* were not significantly different between E11.5 wt and humanized embryonic mouse telencephalon (fig. S2, G to I).

The following primers were used for PCR:

Forward primer for *Kif18a* (5'-AGAAAAGGCGGTGCAGTTCT-3'),

Reverse primer for *Kif18a* (5'-GGAATCTTCCCGACAGCAA-3');

Forward primer for *Kn11* H159R (5'-CCCCAGACAAGTCAAGCAGAA-3'),

Reverse primer for *Kn11* H159R (5'-TCAACTCCATACACTCATTGCC-3');

Forward primer for *Kn11* G1086S (5'-TGGATATCACCAAAGATTGCAC-3'),

Reverse primer for *Kn11* G1086S (5'-CAAACTGAAGCCCTTTCTGTC-3');

Forward primer for *Spag5* D410H and E162G (5'-TGAATCTCGGTTTGTGCGCT-3'),

Reverse primer for *Spag5* D410H and E162G (5'-TTCCTCCCCTGGATCGACAT-3');

Forward primer for *Spag5* P43S (5'-GTTCAAATAGAGCGGCGGG-3'),

Reverse primer for *Spag5* P43S (5'-GTTCTTTCCCACCAGC-TACAAG-3').

The following primers were used for qPCR:

Forward primer for *Kif18a* (5'-CAAACCTCAGGACCACTTGCTGT-3'),

Reverse primer for *Kif18a* (5'-ATGGGAACGAGAAGACACTGC-3');

Forward primer for *Kn11* (5'-CCTCTGGGGGAGATGGCTACAT-3'),

Reverse primer for *Kn11* (5'-GATGGACTTTGTTGGGCTGAGA-3');  
Forward primer for *Spag5* (5'-GTCTCACCTCTTCTTA-CAGGC-3'),

Reverse primer for *Spat5* (5'-GCTGGTTCTGGCACTTCA-TCTA-3');

Forward primer for *Actb* (5'-CGGGACCTGACAGACTACCTC-3'),

Reverse primer for *Actb* (5'-GGTGGTGAAGCTGTAGCCACG-3').

### Genome engineering of human H9 cells

We used an iCRISPR-Cas9n line carrying a doxycycline inducible Cas9D10A nickase in the *AAVS1* locus from the H9 human ESC line (female, WiCell Research Institute, ethics permit AZ 3.04.02/0118) that we generated as previously described (64, 65) and that carries a K3753R (KR) mutation in the *PRKDC* gene to increase editing efficiency as described (66). Cells were grown on Matrigel (Corning, 35248) in mTeSR1 medium (StemCell Technologies, 05852) supplemented with doxycycline (2  $\mu$ g/ml; Clontech, 631311) for 3 days before electroporation and to induce Cas9 nickase expression. Electroporation of oligonucleotides and, in cases when editing with the nickase did not work, ribonucleoprotein (RNP) was carried out using 1 million cells, 78 pmol electroporation enhancer (IDT), 160 pmol of the gRNA (crRNA/tracrR duplex for Cas9 and crRNA for Cpf1), 200 pmol of the respective single-strand DNA (ssDNA) donor, and 252 pmol of Cas9-HiFi or Cpf1-Ultra (both IDT) using the B-16 program of the Nucleofector 2b Device (Lonza) in cuvettes for 100  $\mu$ l of Human Stem Cell nucleofection buffer (Lonza, VVPH-5022). Cells were counted with Countess automated cell counter (Invitrogen).

*KIF18A* was ancestralized using iCRISPR-Cas9 nickase with two gRNAs and ssDNA donor. The ancestralization of *KNL1\_G1086S* was done by Cpf1-Ultra RNP and of *KNL1\_H109R* by Cas9-HiFi RNP. The guides and the donors were purchased as Alt-R crRNAs and DNA oligonucleotides (IDT):

*KIF18A\_sg1*: 5'-TGTTATAAAGAAACAAAATA

*KIF18A\_sg2*: 5'-GATTTGTAGTTTTCTTTCCA

*KNL1\_H109R\_sg1*: 5'-ATTTGCATGTTTCCTTTTCAC

*KNL1\_G1086S\_sg1*: 5'-TGAATGAACCTCTATCAAGCA

ssDNA *KIF18A\_K67R*: 5'-AGTTGACGTTTCATCAAAAACA  
GCATCAAATACAAATTTAAGATCCTTGTGTTTGTCTCTTTA  
T A A C A T T T T G A T T T G T A G T T T T C T T T C A T G -  
GAAAAAACTGACT

ssDNA *KNL1\_H159R*: 5'-TGTTGTAAATGCCTTTTTTAAAAGTT-  
TGCTTTTGTCTGATCTCTTATATTTTGTCTTCATTATAGT  
TTTCAATTAAGAACATACCCATGAAAGGAAACATG-  
CAAATGACCAGACAGTCATTTTTT

ssDNA *KNL1\_G1086S*: 5'-TCTTGTCAATTTTTTAGCTTAAG-  
GCTTTTTCTTCTCTGACTTTTGCCTGATAGAGGTTTC-  
GTTCAGAAATCCAGGACTTTGTACATCTTTGA

To derive colonies from single cells, cells were incubated with StemFlex with supplement (Gibco, A3349401) and CloneR (StemCell Technologies, 05888) for 1 day and then sorted with a Cytina cell printer.

### Validation of edited cell lines

Genomic DNA of each colony was isolated, a region of ~200 base pairs (bp) around the cut site was amplified and sequenced, and from sequences, the editing state was evaluated as described (66).

*KNL1\_G1086S\_F*: 5'-ACACTCTTCCCTACACGACGCTCTT-  
CCGATCTTGATTCAAGCAAACCAACGTGT

*KNL1\_G1086S\_R*: 5'-GTGACTGGAGTTCAGACGTGTGCTCT-  
TCCGATCTTGATGTCAGGTCCATCTGGT

KNL1\_H159R\_F: 5'-ACACTCTTTCCCTACACGACGCTCTTC-  
CGATCTTCCCAAATTGAAACAAATACCTG

KNL1\_H159R\_R: 5'-GTGACTGGAGTTCAGACGTGTGCTCTT-  
CCGATCTTTTTTGTATCCCAAACAAGAAGAA.

KIF18A\_F: 5'-ACACTCTTTCCCTACACGACGCTCTTCCGATC-  
TTCAGCCACTTGCAAAAACATCA

KIF18A\_R: 5'-GTGACTGGAGTTCAGACGTGTGCTCTTC-  
CGATCTTAGAAGCCCCTGCCAAATGG.

Deletions bigger than ~200 bp and therefore not detected by the amplicon sequencing (43, 49) were identified by digital PCR using primer pairs and probes that anneal within the sequenced target regions. A primer pair and probe were also designed for the gene *FOXP2* to serve as a diploid reference. The master mix for droplet digital PCR (ddPCR) amplification included 1× ddPCR Supermix for probes (no dUTP, Bio-Rad), 0.2 μM of each primer and 0.2 μM probe (both IDT) for target and reference, together with 1 μl genomic DNA in QuickExtract DNA Extraction Solution (Lucigen). After droplet generation with the QX200 Droplet generator (Bio-Rad), the PCR was for 5 min at 95°C, followed by 42 cycles of 35 s at 95°C (at a ramp rate of 1.5°C/s) and 65 s at 54°C for *KIF18A* and *KNL1\_G1086S* or 65 s at 56°C for *KNL1\_H109R* (at a ramp rate of 1.5°C/s), and 5 min at 98°C. Readout was in a QX200 Droplet reader (Bio-Rad), and allele copy numbers were determined relative to the *FOXP2* reference and unedited controls.

KNL1\_G1086S\_ddPCR\_L: 5'-AAGATGTACAAAGTCCTGGAT

KNL1\_G1086S\_ddPCR\_R: 5'-CTCTTTATCCTCCAGGGC

KNL1\_G1086S\_probe1: 6-FAM 5'-TGGATATTACCCAGAGTTG-  
TATGGTGGGA BHQ\_1

KNL1\_H159R\_ddPCR\_L: 5'-TATGAAACCATCACTGAGGA

KNL1\_H159R\_ddPCR\_R: 5'-CTGAAAAAATGACT-  
GTCTGGTCA

KNL1\_H159R\_probe1: 6-FAM 5'-TGCCTTTTTAAAGTTT-  
GCTTTTGTCTGA BHQ\_1

KIF18A\_ddPCR\_L: 5'-ATATCCATTCAAAAACTACGAA

KIF18A\_ddPCR\_R: 5'-CCATGGAAAGAAAACACTACAAA

KIF18A\_ddPCR\_probe1: 6-FAM 5'-TGAGTTGACGTTTCAT-  
CAAAAACAGCATCA BHQ\_1

To exclude colonies that experienced a loss-of-heterozygosity at the region near the CRISPR cut site (43), heterozygous variable positions upstream and downstream of the respective target site were amplified and sequenced.

KNL1\_G1086S (upSNP distance: 809 bp and 868 bp; downSNP distance: 254 bp)

KNL1\_G10862\_upSNP\_F: 5'-ACACTCTTTCCCTACACGAC-  
GCTCTTCCGATCTAAGCAATCCCACACCTGACT

KNL1\_G10862\_upSNP\_R: 5'-GTGACTGGAGTTCAGACGT-  
GTGCTCTTCCGATCTCTTTCGTCTCTAACACATCCA

KNL1\_G10862\_downSNP\_F: 5'-ACACTCTTTCCCTACAC-  
GACGCTCTTCCGATCTGCCCTGGAGGATAAAGAGGA

KNL1\_G10862\_downSNP\_R: 5'-GTGACTGGAGTTCAGAC-  
GTGTGCTCTTCCGATCTGAATCGGTGACTTCCAGATCA

KNL1\_H159R (upSNP distance: 2153 bp and 2192 bp; downSNP distance: 1317 bp)

KNL1\_H159R\_upSNP\_F: 5'-ACACTCTTTCCCTACACGAC-  
GCTCTTCCGATCTAAGACCTTCAGAATCCTACCC

KNL1\_H159R\_upSNP\_R: 5'-GTGACTGGAGTTCAGACGT-  
GTGCTCTTCCGATCTTGTATCCTCTGTGTGGCTGAA

KNL1\_H159R\_downSNP\_F: 5'-ACACTCTTTCCCTACAC-  
GACGCTCTTCCGATCTGCAGAGCCTGTCAAATCCTT

KNL1\_H159R\_downSNP\_R: 5'-GTGACTGGAGTTCAGAC-  
GTGTGCTCTTCCGATCTCCAGGTGTCGGTTAAGCTGT

KIF18A (upSNP distance: 24343 bp; downSNP distance: 30555 bp)

KIF18A\_upSNP\_F: 5'-ACACTCTTTCCCTACACGACGCTCTT-  
CCGATCTGTGGGTAAGGGAGTGGGAAT

KIF18A\_upSNP\_R: 5'-GTGACTGGAGTTCAGACGTGTGCTCT-  
TCCGATCTGCTTCAGAGCCTGCACCTT

KIF18A\_downSNP\_F: 5'-ACACTCTTTCCCTACACGACGCT-  
CTTCCGATCTGCAACCGTTTTAGCCAAGAT

KIF18A\_downSNP\_R: 5'-GTGACTGGAGTTCAGACGTGT-  
GCTCTTCCGATCTCTCCCCGAATGTCTTTCTCA

To find large-scale chromosomal deletions, duplications, or karyotype abnormalities, we performed “shallow” whole genome sequencing to an average genome coverage 0.10 to 0.15 of edited and nonedited colonies as well as the cell line from which the colonies were derived, as described (66).

Expression of *KIF18a* and *KNL1* in edited and nonedited cell lines as well as their “mother” cell line was measured with CellsDirect One-Step qRT-PCR Kit (Invitrogen) using TaqMan probes for *KIF18a* (FAM Hs0105428\_m1), *KNL1* (FAM Hs00538241\_m1), and a “housekeeping gene” *PPIB* (VIC Hs00168719\_m1). The producer’s protocol was followed to set up reactions. For a subset of reactions, reverse transcriptase was inactivated by 15-min incubation at 70°C. The cycler program for RT-qPCR was 50°C for 10 min, 95°C for 2 min, then 50 cycles of 95°C for 3 s, 53°C for 15 s, and 60°C for 30 s.

### Generation of cerebral organoids

Organoids were generated from the H9 ESCs and cultured as described (67, 68) with the exceptions that TrypLE was used instead of Accutase, ROCK inhibitor was used on the first 2 days, mTeSR1 was used instead of low-bFGF hESC medium in 96-well ultralow attachment plates during embryoid body (EB) formation, neural induction medium was given from day 4, embedding was on day 9 with B27 in the differentiation medium, and vitamin A was added on day 15. On days 27 to 32, they were fixed, embedded, cryosectioned, and prepared for immunohistochemistry as described (18). Fixation was with 4% paraformaldehyde (PFA) in 120 mM phosphate buffer (pH 7.4) for 2 hours at room temperature followed by overnight incubation at 4°C.

### Neocortex tissue

E11.5 mouse neocortex tissue was dissected at room temperature in phosphate-buffered saline. The dorsolateral telencephalon, at a medial position along the rostro-caudal axis, was used for live-tissue imaging (unfixed) and immunohistochemistry (fixed). Mouse neocortex was fixed, embedded, cryosectioned, and prepared for immunohistochemistry as described (18, 69), except that fixation was with 1% PFA in 120 mM phosphate buffer (pH 7.4) for 30 min at room temperature. Human neocortex tissue was fixed with 4% PFA in 120 mM phosphate buffer (pH 7.4) for 3 hours at room temperature followed by overnight incubation at 4°C.

### Immunohistochemistry

Immunohistochemistry was performed as described (18, 69). Analyses of SAC-positive kinetochores, as well as of lagging chromosomes, was performed using 3D stacks of serial confocal sections, of typically 512 × 512 pixels × 16 to 25 z-sections (xyz sampling: 0.09 × 0.09 × 0.75 μm). The following primary antibodies were used: anti-BUBR1 mouse monoclonal (1:100 dilution; BD Biosciences),



CREST anti-centromere (kinetochore) human polyclonal (1:50; Antibodies Incorporated), anti-MAD1 mouse monoclonal (1:100; Millipore), anti-FOXG1 rabbit polyclonal (1:300; Abcam), anti Brn2 goat polyclonal (Santa Cruz Biotechnology, 1:100), and Ctip2 rat monoclonal (Abcam, 1:200). The secondary antibodies used (1:500 dilution) in combination with 4',6-diamidino-2-phenylindole staining were all donkey derived, conjugated with Alexa 488, 555, or 647 (Life Technologies), except goat anti-human conjugated with Alexa 488 (Life Technologies).

### Live imaging

Live-tissue and -cell imaging were performed as described (18, 69). In short, freshly dissected developing neocortex tissue or organoids were embedded in agarose (Sigma-Aldrich, Germany), sectioned (~200  $\mu\text{m}$ ) with a vibratome (Leica, Germany), embedded in type Ia collagen (Cellmatrix, Japan), mounted in glass bottom microwell dishes (MatTek, Germany), and incubated with Hoechst 33342 for organoids (Sigma-Aldrich) or Sir-DNA for mice (Spirochrome) as vital DNA dye. Tissue slices in the dish were cultured in a microscope stage incubation chamber (Pecon, Germany) at 37°C. The H9 ESC monolayer cultures were mounted in glass bottom microwell dishes coated for 1 hour with Matrigel (BD Bioscience) and imaged under standard cell culture conditions. Analysis of mitotic-phase durations was performed on time-lapse 3D stacks of serial two-photon sections of typically 512  $\times$  512 pixels  $\times$  7 to 9 z-sections (xyzt sampling: 0.7  $\times$  0.7  $\times$  2.2  $\mu\text{m}$   $\times$  1.5 to 2.5 min), acquired for 6 to 12 hours.

### Microscopy

Fixed—as well as live—images were recorded with a Zeiss LSM 780 NLO single/multiphoton point scanning system, with tunable pulsed near-infrared laser (Chameleon Vision II) for multiphoton excitation, and using 63 $\times$  Plan-Apochromat 1.4 numerical aperture (NA) oil or 40 $\times$  C-Apochromat 1.2 NA W objectives (Carl Zeiss, Germany).

### Quantifications

Images were viewed and prepared with ImageJ (<http://imagej.nih.gov/ij/>). Brightness and contrast were recorded and adjusted linearly. Measurements of mitotic phases were performed as described (18). In short, the time of chromosome congression toward a metaphase plate is referred to as “congression” or “prometaphase”; the time between the formation of a tight metaphase plate and chromatid segregation onset is referred to as “metaphase”; the time between the onset of chromatid segregation and the onset of general chromosome decondensation onset is referred to as “anaphase”; and the time between the beginning of chromosome decondensation until a level indistinguishable from interphase is referred to as “telophase.” Given the low incidence of lagging chromosomes, the percentage of AP divisions with lagging chromosomes was determined by adding all cells from all independent experiments per tissue to a single, cumulative percentage for each. Quantifications of AP mitotic phases, SAC markers, and lagging chromosomes in mouse neocortex were performed by a blinded observer (F.M.B.), and lagging chromosomes in mouse neocortex and organoids were cross-checked by another blinded observer (C.H.). Quantifications of AP metaphase durations in organoids were reproduced by a blinded observer (W.B.H). Measurements of cortical thickness, cortical perimeter, and cortical neuron numbers in adult mice were performed as described (70).

### Statistical analysis

Cell and tissue data were plotted and analyzed with GraphPad Prism (La Jolla, CA). Because at least some datasets in most experiments did not pass normality tests (Shapiro-Wilk and Kolmogorov-Smirnov tests), nonparametric Mann-Whitney *U* tests were typically used for two groups of observations and Kruskal-Wallis tests with Dunn’s correction for multiple comparisons for three or more groups. For gene expression and cortical morphology and neuron analysis in mice, the two-tailed unpaired Student’s *t* test was used.

### SUPPLEMENTARY MATERIALS

Supplementary material for this article is available at <https://science.org/doi/10.1126/sciadv.abn7702>

[View/request a protocol for this paper from Bio-protocol.](#)

### REFERENCES AND NOTES

1. P. Rakic, Evolution of the neocortex: A perspective from developmental biology. *Nat. Rev. Neurosci.* **10**, 724–735 (2009).
2. C. J. Donahue, M. F. Glasser, T. M. Preuss, J. K. Rilling, D. C. Van Essen, Quantitative assessment of prefrontal cortex in humans relative to nonhuman primates. *Proc. Natl. Acad. Sci. U.S.A.* **115**, E5183–E5192 (2018).
3. J. H. Lui, D. V. Hansen, A. R. Kriegstein, Development and evolution of the human neocortex. *Cell* **146**, 18–36 (2011).
4. E. Taverna, M. Götz, W. B. Huttner, The cell biology of neurogenesis: Toward an understanding of the development and evolution of the neocortex. *Annu. Rev. Cell Dev. Biol.* **30**, 465–502 (2014).
5. D. Jayaraman, B. I. Bae, C. A. Walsh, The genetics of primary microcephaly. *Annu. Rev. Genomics Hum. Genet.* **19**, 177–200 (2018).
6. V. Borrell, Recent advances in understanding neocortical development. *F1000Res* **8**, F1000 (2019).
7. Z. Molnar, G. J. Clowry, N. Sestan, A. Alzu'bi, T. Bakken, R. F. Hevner, P. S. Huppi, I. Kostovic, P. Rakic, E. S. Anton, D. Edwards, P. Garcez, A. Hoerder-Suabedissen, A. Kriegstein, New insights into the development of the human cerebral cortex. *J. Anat.* **235**, 432–451 (2019).
8. S. Vaid, W. B. Huttner, Transcriptional regulators and human-specific/primate-specific genes in neocortical neurogenesis. *Int. J. Mol. Sci.* **21**, 4614 (2020).
9. W. Enard, M. Przeworski, S. E. Fisher, C. S. L. Lai, V. Wiebe, T. Kitano, A. P. Monaco, S. Pääbo, Molecular evolution of FOXP2, a gene involved in speech and language. *Nature* **418**, 869–872 (2002).
10. W. Enard, S. Gehre, K. Hammerschmidt, S. M. Hölter, T. Blass, M. Somel, M. K. Brückner, C. Schreiweis, C. Winter, R. Sohr, L. Becker, V. Wiebe, B. Nickel, T. Giger, U. Müller, M. Groszer, T. Adler, A. Aguilar, I. Bolle, J. Calzada-Wack, C. Dalke, N. Ehrhardt, J. Favor, H. Fuchs, V. Gailus-Durner, W. Hans, G. Hölzlwimmer, A. Javaheri, S. Kalaydjiev, M. Kallnik, E. Kling, S. Kunder, I. Mossbrugger, B. Naton, I. Racz, B. Rathkolb, J. Rozman, A. Schrewe, D. H. Busch, J. Graw, B. Ivandic, M. Klingenspor, T. Klopstock, M. Ollert, L. Quintanilla-Martinez, H. Schulz, E. Wolf, W. Wurst, A. Zimmer, S. E. Fisher, R. Morgenstern, T. Arendt, M. H. de Angelis, J. Fischer, J. Schwarz, S. Pääbo, A humanized version of Foxp2 affects cortico-basal ganglia circuits in mice. *Cell* **137**, 961–971 (2009).
11. M. Y. Dennis, X. Nuttle, P. H. Sudmant, F. Antonacci, T. A. Graves, M. Nefedov, J. A. Rosenfeld, S. Sajjadian, M. Malig, H. Kotkiewicz, C. J. Curry, S. Shafer, L. G. Shaffer, P. J. de Jong, R. K. Wilson, E. E. Eichler, Evolution of human-specific neural SRGAP2 genes by incomplete segmental duplication. *Cell* **149**, 912–922 (2012).
12. C. Charrier, K. Joshi, J. Coutinho-Budd, J. E. Kim, N. Lambert, J. de Marchena, W. L. Jin, P. Vanderhaeghen, A. Ghosh, T. Sassa, F. Polleux, Inhibition of SRGAP2 function by its human-specific paralogs induces neoteny during spine maturation. *Cell* **149**, 923–935 (2012).
13. C. Schreiweis, U. Bornschein, E. Burguiere, C. Kerimoglu, S. Schreiter, M. Dannemann, S. Goyal, E. Rea, C. A. French, R. Puliyadi, M. Groszer, S. E. Fisher, R. Mundry, C. Winter, W. Hevers, S. Pääbo, W. Enard, A. M. Graybiel, Humanized Foxp2 accelerates learning by enhancing transitions from declarative to procedural performance. *Proc. Natl. Acad. Sci. U.S.A.* **111**, 14253–14258 (2014).
14. E. R. E. Schmidt, H. T. Zhao, J. M. Park, M. Dipoppa, M. M. Monsalve-Mercado, J. B. Dahan, C. C. Rodgers, A. Lejeune, E. M. C. Hillman, K. D. Miller, R. M. Bruno, F. Polleux, A human-specific modifier of cortical connectivity and circuit function. *Nature* **599**, 640–644 (2021).
15. M. Heide, W. B. Huttner, F. Mora-Bermúdez, Brain organoids as models to study human neocortex development and evolution. *Curr. Opin. Cell Biol.* **55**, 8–16 (2018).
16. I. Chiaradia, M. A. Lancaster, Brain organoids for the study of human neurobiology at the interface of in vitro and in vivo. *Nat. Neurosci.* **23**, 1496–1508 (2020).



17. S. Velasco, B. Paulsen, P. Arlotta, 3D brain organoids: Studying brain development and disease outside the embryo. *Annu. Rev. Neurosci.* **43**, 375–389 (2020).
18. F. Mora-Bermúdez, F. Badsha, S. Kanton, J. G. Camp, B. Vernot, K. Köhler, B. Voigt, K. Okita, T. Maricic, Z. He, R. Lachmann, S. Pääbo, B. Treutlein, W. B. Huttner, Differences and similarities between human and chimpanzee neural progenitors during cerebral cortex development. *eLife* **5**, e18683 (2016).
19. T. J. Mitchison, E. D. Salmon, Mitosis: A history of division. *Nat. Cell Biol.* **3**, E17–E21 (2001).
20. I. M. Cheeseman, The kinetochore. *Cold Spring Harb. Perspect. Biol.* **6**, a015826 (2014).
21. A. Musacchio, A. Desai, A molecular view of kinetochore assembly and function. *Biology (Basel)* **6**, 5 (2017).
22. S. M. Hinshaw, S. C. Harrison, Kinetochore function from the bottom up. *Trends Cell Biol.* **28**, 22–33 (2018).
23. A. Musacchio, E. D. Salmon, The spindle-assembly checkpoint in space and time. *Nat. Rev. Mol. Cell Biol.* **8**, 379–393 (2007).
24. N. London, S. Biggins, Signalling dynamics in the spindle checkpoint response. *Nat. Rev. Mol. Cell Biol.* **15**, 736–748 (2014).
25. E. A. Foley, T. M. Kapoor, Microtubule attachment and spindle assembly checkpoint signalling at the kinetochore. *Nat. Rev. Mol. Cell Biol.* **14**, 25–37 (2013).
26. A. Musacchio, The molecular biology of spindle assembly checkpoint signaling dynamics. *Curr. Biol.* **25**, R1002–R1018 (2015).
27. K. Prüfer, C. de Filippo, S. Grote, F. Mafessoni, P. Korlević, M. Hajdinjak, B. Vernot, L. Skov, P. Hsieh, S. Peyrégne, D. Reher, C. Hopfe, S. Nagel, T. Maricic, Q. Fu, C. Theunert, R. Rogers, P. Skoglund, M. Chintalapati, M. Dannemann, B. J. Nelson, F. M. Key, P. Rudan, Ž. Kucčan, I. Gusić, L. V. Golovanova, V. B. Doronichev, N. Patterson, D. Reich, E. E. Eichler, M. Slatkin, M. H. Schierup, A. M. Andrés, J. Kelso, M. Meyer, S. Pääbo, A high-coverage Neandertal genome from Vindija Cave in Croatia. *Science* **358**, 655–658 (2017).
28. S. Pääbo, The human condition—A molecular approach. *Cell* **157**, 216–226 (2014).
29. F. Mora-Bermúdez, E. Taverna, W. B. Huttner, From stem and progenitor cells to neurons in the developing neocortex: Key differences among hominids. *FEBS J.* **289**, 1524–1535 (2022).
30. F. Mora-Bermúdez, W. B. Huttner, What are the human-specific aspects of neocortex development? *Front. Neurosci.* **16**, 878950 (2022).
31. M. I. Mayr, S. Hummer, J. Bormann, T. Gruner, S. Adio, G. Woehlke, T. U. Mayer, The human kinesin Kif18A is a motile microtubule depolymerase essential for chromosome congression. *Curr. Biol.* **17**, 488–498 (2007).
32. J. Hafner, M. I. Mayr, M. M. Mochel, T. U. Mayer, Pre-anaphase chromosome oscillations are regulated by the antagonistic activities of Cdk1 and PP1 on Kif18A. *Nat. Commun.* **5**, 4397 (2014).
33. J. Stumpff, M. Wagenbach, A. Franck, C. L. Asbury, L. Wordeman, Kif18A and chromokinesins confine centromere movements via microtubule growth suppression and spatial control of kinetochore tension. *Dev. Cell* **22**, 1017–1029 (2012).
34. I. M. Cheeseman, T. Hori, T. Fukagawa, A. Desai, KNL1 and the CENP-H/I/K complex coordinately direct kinetochore assembly in vertebrates. *Mol. Biol. Cell* **19**, 587–594 (2008).
35. A. Genin, J. Desir, N. Lambert, M. Biervliet, N. Van Der Aa, G. Pierquin, A. Killian, M. Tosi, M. Urbina, A. Lefort, F. Libert, I. Pirson, M. Abramowicz, Kinetochore KMN network gene CAS5 mutated in primary microcephaly. *Hum. Mol. Genet.* **21**, 5306–5317 (2012).
36. G. Zhang, T. Kruse, B. Lopez-Mendez, K. B. Sylvestersen, D. H. Garvanska, S. Schopper, M. L. Nielsen, J. Nilsson, Bub1 positions Mad1 close to KNL1 MELT repeats to promote checkpoint signalling. *Nat. Commun.* **8**, 15822 (2017).
37. A. O. Javed, Y. Li, J. Muffat, K.-C. Su, M. A. Cohen, T. Lungjangwa, P. Aubourg, I. M. Cheeseman, R. Jaenisch, Microcephaly modeling of kinetochore mutation reveals a brain-specific phenotype. *Cell Rep.* **25**, 368–382.e5 (2018).
38. G. J. Mack, D. A. Compton, Analysis of mitotic microtubule-associated proteins using mass spectrometry identifies astrin, a spindle-associated protein. *Proc. Natl. Acad. Sci. U.S.A.* **98**, 14434–14439 (2001).
39. M. S. Chang, C. J. Huang, M. L. Chen, S. T. Chen, C. C. Fan, J. M. Chu, W. C. Lin, Y. C. Yang, Cloning and characterization of hMAP126, a new member of mitotic spindle-associated proteins. *Biochem. Biophys. Res. Commun.* **287**, 116–121 (2001).
40. K. H. Thein, J. Kleylein-Sohn, E. A. Nigg, U. Gruneberg, Astrin is required for the maintenance of sister chromatid cohesion and centrosome integrity. *J. Cell Biol.* **178**, 345–354 (2007).
41. A. L. Manning, S. F. Bakhoum, S. Maffini, C. Correia-Melo, H. Maiato, D. A. Compton, CLASP1, astrin and Kif2b form a molecular switch that regulates kinetochore-microtubule dynamics to promote mitotic progression and fidelity. *EMBO J.* **29**, 3531–3543 (2010).
42. C. L. Rieder, A. Schultz, R. Cole, G. Sluder, Anaphase onset in vertebrate somatic cells is controlled by a checkpoint that monitors sister kinetochore attachment to the spindle. *J. Cell Biol.* **127**, 1301–1310 (1994).
43. I. Weisheit, J. A. Kroeger, R. Malik, J. Klimmt, D. Crusius, A. Dannert, M. Dichgans, D. Paquet, Detection of deleterious on-target effects after HDR-mediated CRISPR editing. *Cell Rep.* **31**, 107689 (2020).
44. S. A. Fietz, R. Lachmann, H. Brandl, M. Kircher, N. Samusik, R. Schroder, N. Lakshmanaperumal, I. Henry, J. Vogt, A. Riehn, W. Distler, R. Nitsch, W. Enard, S. Pääbo, W. B. Huttner, Transcripts of germinal zones of human and mouse fetal neocortex suggest a role of extracellular matrix in progenitor self-renewal. *Proc. Natl. Acad. Sci. U.S.A.* **109**, 11836–11841 (2012).
45. K. Prüfer, F. Racimo, N. Patterson, F. Jay, S. Sankararaman, S. Sawyer, A. Heinze, G. Renaud, P. H. Sudmant, C. de Filippo, H. Li, S. Mallick, M. Dannemann, Q. Fu, M. Kircher, M. Kuhlwilm, M. Lachmann, M. Meyer, M. Ongyerth, M. Siebauer, C. Theunert, A. Tandon, P. Moorjani, J. Pickrell, J. C. Mullikin, S. H. Vohr, R. E. Green, I. Hellmann, P. L. F. Johnson, H. Blanche, H. Cann, J. O. Kitzman, J. Shendure, E. E. Eichler, E. S. Lein, T. E. Bakken, L. V. Golovanova, V. B. Doronichev, M. V. Shunkov, A. P. Derevianko, B. Viola, M. Slatkin, D. Reich, J. Kelso, S. Pääbo, The complete genome sequence of a Neanderthal from the Altai Mountains. *Nature* **505**, 43–49 (2014).
46. D. Varma, E. D. Salmon, The KMN protein network – Chief conductors of the kinetochore orchestra. *J. Cell Sci.* **125**, 5927–5936 (2012).
47. P. Ghongane, M. Kapanidou, A. Asghar, S. Elowe, V. M. Bolanos-Garcia, The dynamic protein Knl1 – A kinetochore rendezvous. *J. Cell Sci.* **127**, 3415–3423 (2014).
48. H. Y. Shin, C. Wang, H. K. Lee, K. H. Yoo, X. Zeng, T. Kuhns, C. M. Yang, T. Mohr, C. Liu, L. Hennighausen, CRISPR/Cas9 targeting events cause complex deletions and insertions at 17 sites in the mouse genome. *Nat. Commun.* **8**, 15464 (2017).
49. T. Maricic, N. Helmbrecht, S. Riesenberger, D. Macak, P. Kanis, M. Lackner, A. D. Pugach-Matveeva, S. Pääbo, Comment on “Reintroduction of the archaic variant of *NOVA1* in cortical organoids alters neurodevelopment”. *Science* **374**, eabi6060 (2021).
50. C. A. Trujillo, E. S. Rice, N. K. Schaefer, I. A. Chaim, E. C. Wheeler, A. A. Madrigal, J. Buchanan, S. Preissl, A. Wang, P. D. Negraes, R. A. Szeto, R. H. Herai, A. Huseynov, M. S. A. Ferraz, F. S. Borges, A. H. Kihara, A. Byrne, M. Marin, C. Vollmers, A. N. Brooks, J. D. Lutz, K. Semendeferi, B. Shapiro, G. W. Ye, S. E. P. Smith, R. E. Green, A. R. Muotri, Reintroduction of the archaic variant of *NOVA1* in cortical organoids alters neurodevelopment. *Science* **371**, eaax2537 (2021).
51. R. H. Herai, R. A. Szeto, C. A. Trujillo, A. R. Muotri, Response to comment on “Reintroduction of the archaic variant of *NOVA1* in cortical organoids alters neurodevelopment”. *Science* **374**, eabi9881 (2021).
52. V. Stepanova, K. E. Moczulska, G. N. Vacano, I. Kurochkin, X. Ju, S. Riesenberger, D. Macak, T. Maricic, L. Dombrowski, M. Schornig, K. Anastasiadis, O. Baker, R. Naumann, E. Khrameeva, A. Vanushkina, E. Stekolshchikova, A. Egorova, A. Tkachev, R. Mazzarino, N. Duval, D. Zubkov, P. Gialvisco, T. G. Wilkinson, D. Patterson, P. Khaïtovich, S. Pääbo, Reduced purine biosynthesis in humans after their divergence from Neandertals. *eLife* **10**, e58741 (2021).
53. F. Mora-Bermúdez, W. B. Huttner, Novel insights into mammalian embryonic neural stem cell division: Focus on microtubules. *Mol. Biol. Cell* **26**, 4302–4306 (2015).
54. P. Rakic, Specification of cerebral cortical areas. *Science* **241**, 170–176 (1988).
55. H. van den Bos, D. C. J. Spierings, A. S. Taudt, B. Bakker, D. Porubský, E. Falconer, C. Novoa, N. Halsema, H. G. Kazemier, K. Hoekstra-Wakker, V. Guryev, W. F. A. den Dunnen, F. Fojter, M. C. Tatché, H. W. G. M. Boddeke, P. M. Lansdorp, Single-cell whole genome sequencing reveals no evidence for common aneuploidy in normal and Alzheimer’s disease neurons. *Genome Biol.* **17**, 116 (2016).
56. S. Rohrbach, B. Siddoway, C. S. Liu, J. Chun, Genomic mosaicism in the developing and adult brain. *Dev. Neurobiol.* **78**, 1026–1048 (2018).
57. G. A. Andriani, E. Maggi, D. Pique, S. E. Zimmerman, M. Lee, W. Quispe-Tintaya, A. Maslov, J. Campisi, J. Vijg, J. C. Mar, C. Montagna, A direct comparison of interphase FISH versus low-coverage single cell sequencing to detect aneuploidy reveals respective strengths and weaknesses. *Sci. Rep.* **9**, 10508 (2019).
58. I. Ganmore, G. Smooha, S. Izraeli, Constitutional aneuploidy and cancer predisposition. *Hum. Mol. Genet.* **18**, R84–R93 (2009).
59. S. Santaguida, A. Amon, Short- and long-term effects of chromosome mis-segregation and aneuploidy. *Nat. Rev. Mol. Cell Biol.* **16**, 473–485 (2015).
60. M. A. Sherman, R. E. Rodin, G. Genovese, C. Dias, A. R. Barton, R. E. Mukamel, B. Berger, P. J. Park, C. A. Walsh, P. R. Loh, Large mosaic copy number variations confer autism risk. *Nat. Neurosci.* **24**, 197–203 (2021).
61. B. Chen, L. A. Gilbert, B. A. Cimini, J. Schnitzbauer, W. Zhang, G. W. Li, J. Park, E. H. Blackburn, J. S. Weissman, L. S. Qi, B. Huang, Dynamic imaging of genomic loci in living human cells by an optimized CRISPR/Cas system. *Cell* **155**, 1479–1491 (2013).
62. K. Vintersten, G. Testa, R. Naumann, K. Anastasiadis, A. F. Stewart, Bacterial artificial chromosome transgenesis through pronuclear injection of fertilized mouse oocytes. *Methods Mol. Biol.* **415**, 83–100 (2008).
63. M. Arras, P. Autenried, A. Rettich, D. Spaeni, T. Rulicke, Optimization of intraperitoneal injection anesthesia in mice: Drugs, dosages, adverse effects, and anesthesia depth. *Comp. Med.* **51**, 443–456 (2001).
64. F. Gonzalez, Z. Zhu, Z. D. Shi, K. Lelli, N. Verma, Q. V. Li, D. Huangfu, An iCRISPR platform for rapid, multiplexable, and inducible genome editing in human pluripotent stem cells. *Cell Stem Cell* **15**, 215–226 (2014).

65. S. Riesenberg, T. Maricic, Targeting repair pathways with small molecules increases precise genome editing in pluripotent stem cells. *Nat. Commun.* **9**, 2164 (2018).
66. S. Riesenberg, M. Chintalapati, D. Macak, P. Kanis, T. Maricic, S. Pääbo, Simultaneous precise editing of multiple genes in human cells. *Nucleic Acids Res.* **47**, e116 (2019).
67. M. A. Lancaster, M. Renner, C. A. Martin, D. Wenzel, L. S. Bicknell, M. E. Hurler, T. Homfray, J. M. Penninger, A. P. Jackson, J. A. Knoblich, Cerebral organoids model human brain development and microcephaly. *Nature* **501**, 373–379 (2013).
68. M. A. Lancaster, J. A. Knoblich, Generation of cerebral organoids from human pluripotent stem cells. *Nat. Protoc.* **9**, 2329–2340 (2014).
69. F. Mora-Bermúdez, F. Matsuzaki, W. B. Huttner, Specific polar subpopulations of astral microtubules control spindle orientation and symmetric neural stem cell division. *eLife* **3**, e02875 (2014).
70. L. Xing, A. Kubik-Zahorodna, T. Namba, A. Pinson, M. Florio, J. Prochazka, M. Sarov, R. Sedlacek, W. B. Huttner, Expression of human-specific ARHGAP11B in mice leads to neocortex expansion and increased memory flexibility. *EMBO J.* **40**, e107093 (2021).

**Acknowledgments:** We thank members of the Huttner and Pääbo groups for the useful discussions. We apologize to authors whose work we could not refer to due to space constraints. We thank the Services and Facilities of the Max Planck Institute of Molecular Cell Biology and Genetics for expert technical support, notably J. Peychl and the team of the Light Microscopy Facility and J. Helppi and the team of the Biomedical Services (BMS), and the teams in the

Transgenics, Genome Engineering, and Genotyping Facilities. We thank D. Wollny for generating the H9 iCRISPR cell line. **Funding:** This work was funded by the Max Planck Society (W.B.H. and S.P.), ERA-NET NEURON (MicroKin) (W.B.H.), and the NOMIS Foundation (S.P.).

**Author contributions:** F.M.-B. conceived, designed, performed, and analyzed the experiments, designed gene-edited mice, optimized and generated cerebral organoids, and wrote the manuscript. P.K. and D.M. did genome engineering of human stem cells and validated edited cellular clones. J.P. optimized and generated cerebral organoids. R.N. designed and generated gene-edited mice. L.X. analyzed gene expression, cortical dimensions, and neuron numbers in mice. M.S. designed gene-edited mice. S.W. designed mouse genotyping. C.E.O. generated cerebral organoids. C.H. cross-checked data. P.W. provided fetal human tissue and relevant information. S.R. did genome engineering of human stem cells and validated edited cellular clones. T.M. validated edited cellular clones. W.B.H. supervised the study, cross-checked and reproduced data, and wrote the manuscript. S.P. supervised the study and wrote the manuscript. **Competing interests:** The authors declare that they have no competing interests. **Data and materials availability:** All data needed to evaluate the conclusions in the paper are available in the paper and/or the Supplementary Materials.

Submitted 18 December 2021

Accepted 15 June 2022

Published 29 July 2022

10.1126/sciadv.abn7702